Advances in the Pathogenesis of Hematopoietic Neoplasms
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Pathophysiology".
Deadline for manuscript submissions: 31 December 2025 | Viewed by 134
Special Issue Editors
Interests: hematopathology; molecular pathology; lymphoma; leukemia; genomics; bioinformatics
Special Issues, Collections and Topics in MDPI journals
Interests: hematology; targeted therapy; lymphoma; genomics
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Hematologic neoplasms are classified, in the fifth edition of the WHO classification and the international consensus classification, using diagnostic criteria based on clinicopathological, morphologic, immunophenotypic, molecular, and cytogenetic features. The major categories of hematopoietic neoplasms include myeloproliferative neoplasms, myelodysplastic syndromes, myeloproliferative/myelodysplastic neoplasms, acute myeloid leukemia, B cell neoplasms, T cell neoplasms, histiocytic/dendritic cell neoplasms, and stromal-derived neoplasms of lymphoid tissues. In recent years, major advances have been made in our understanding of these neoplasms fueled by advances in genomics and proteomics such as single-cell sequencing and spatial biology. In this Special Issue, we aim to review our current understanding of the major categories of hemopoietic neoplasms, focusing on advances in molecular pathogenesis and implications for diagnosis and therapy.
Dr. Raju K. Pillai
Dr. Steven T. Rosen
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- B cell lymphoma
- T cell lymphoma
- Hodgkin lymphoma
- leukemia
- myeloma
- pathogenesis
- genomics
- microenvironment
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
